Lundbeck’s migraine prevention treatment sees ph. 2 success after trial’s earlier setback
Lundbeck’s intravenous monoclonal antibody significantly reduced the number of monthly migraine days compared to placebo in a phase 2b study after the company had previously discontinued a subcutaneous portion of the trial.
In the dose finding study of 431 patients who had not responded to prior preventative treatments, multiple intravenous doses led to a statistically significant drop in monthly migraine days over 12 weeks and were reported as well tolerated. The results came from the multiple IV dosing portion of the trial after a prespecified interim futility analysis led Lundbeck to halt development of the subcutaneous delivery method. “These data underline Lundbeck’s ambition to deliver the first PACAP targeting option in migraine prevention,” said Johan Luthman, Ph.D., EVP and head of R&D at Lundbeck.
The continued clinical progress of PACAP targeted therapies contributes to the broader innovation ecosystem shaping the future of neurological drug development.